Rani Therapeutics Holdings is a biotechnology business based in the US. Rani Therapeutics Holdings shares (RANI) are listed on the NASDAQ and all prices are listed in US Dollars. Rani Therapeutics Holdings employs 114 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Rani Therapeutics Holdings stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – RANI. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Rani Therapeutics Holdings stock price (NASDAQ: RANI)
Use our graph to track the performance of RANI stocks over time.Rani Therapeutics Holdings shares at a glance
Latest market close | $5.90 |
---|---|
52-week range | $5.11 - $27.13 |
50-day moving average | $7.04 |
200-day moving average | $9.52 |
Wall St. target price | $23.63 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.11 |
Buy Rani Therapeutics Holdings stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Rani Therapeutics Holdings stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Rani Therapeutics Holdings price performance over time
Historical closes compared with the close of $5.9 from 2023-01-25
1 week (2023-01-20) | -3.12% |
---|---|
1 month (2022-12-27) | 5.36% |
3 months (2022-10-27) | -2.16% |
6 months (2022-07-27) | -48.96% |
1 year (2022-01-25) | -69.51% |
---|---|
2 years (2021-01-23) | N/A |
3 years (2020-01-23) | N/A |
5 years (2018-01-23) | N/A |
Rani Therapeutics Holdings financials
Gross profit TTM | $2.7 million |
---|---|
Return on assets TTM | -30.25% |
Return on equity TTM | -54.33% |
Profit margin | 0% |
Book value | $1.71 |
Market capitalisation | $309.1 million |
TTM: trailing 12 months
Rani Therapeutics Holdings share dividends
We're not expecting Rani Therapeutics Holdings to pay a dividend over the next 12 months.
Rani Therapeutics Holdings overview
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California. .
Rani Therapeutics Holdings in the news
Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference
Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update
Frequently asked questions
What percentage of Rani Therapeutics Holdings is owned by insiders or institutions?Currently 59.876% of Rani Therapeutics Holdings shares are held by insiders and 11.281% by institutions. How many people work for Rani Therapeutics Holdings?
Latest data suggests 114 work at Rani Therapeutics Holdings. When does the fiscal year end for Rani Therapeutics Holdings?
Rani Therapeutics Holdings's fiscal year ends in December. Where is Rani Therapeutics Holdings based?
Rani Therapeutics Holdings's address is: 2051 Ringwood Avenue, San Jose, CA, United States, 95131 What is Rani Therapeutics Holdings's ISIN number?
Rani Therapeutics Holdings's international securities identification number is: US7530181004
More guides on Finder
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
-
Best international stock brokers for 2023
We explore some of the best brokerage accounts for international stock trading. Here’s what you need to know.
Ask an Expert